| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 21,502 | 23,859 | 22,538 | 20,387 |
| Cost of goods sold | 5,450 | 6,655 | 6,196 | 5,361 |
| Gross profit | 16,052 | 17,204 | 16,342 | 15,026 |
| Research and development | 4,846 | 5,306 | 4,756 | 3,744 |
| Selling, general and administrative | 25,599 | 26,702 | 26,149 | 25,411 |
| Total operating expenses | 30,445 | 32,008 | 30,905 | 29,155 |
| Loss from operations | -14,393 | -14,804 | -14,563 | -14,129 |
| Interest income | 611 | 723 | 864 | 1,269 |
| Interest expense | 805 | 799 | 781 | 891 |
| Other income (expense), net | 758 | -116 | 167 | -201 |
| Net loss before tax | -13,829 | -14,996 | -14,313 | -13,952 |
| Income tax expense | 128 | 177 | 135 | 192 |
| Net loss | -13,957 | -15,173 | -14,448 | -14,144 |
| Currency translation adjustment | -399 | 435 | 111 | 412 |
| Change in unrealized gains (losses) on marketable securities | 1 | -1 | -22 | 149 |
| Total other comprehensive (loss) income | -398 | 434 | 89 | 561 |
| Comprehensive loss | -14,355 | -14,739 | -14,359 | -13,583 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.34 | -0.38 | -0.36 | -0.36 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.34 | -0.38 | -0.36 | -0.36 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 40,936,896 | 40,429,655 | 39,954,658 | 39,276,447 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 40,936,896 | 40,429,655 | 39,954,658 | 39,276,447 |
Pulmonx Corp (LUNG)
Pulmonx Corp (LUNG)